Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Donatella Marazziti, Federico Mucci, Valentina Falaschi & Liliana Dell’Osso. (2019) Asenapine for the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 20:11, pages 1321-1330.
Read now
Read now
Heinz Grunze, Eduard Vieta, Guy M. Goodwin, Charles Bowden, Rasmus W. Licht, Jean-Michel Azorin, Lakshmi Yatham, Sergey Mosolov, Hans-Jürgen Möller & Siegfried Kasper. (2018) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. The World Journal of Biological Psychiatry 19:1, pages 2-58.
Read now
Read now
Thomas Scheidemantel, Irina Korobkova, Soham Rej & Martha Sajatovic. (2015) Asenapine for bipolar disorder. Neuropsychiatric Disease and Treatment 11, pages 3007-3017.
Read now
Read now
Brian Godman. (2015) The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine. Journal of Medical Economics 18:11, pages 871-873.
Read now
Read now
Articles from other publishers (11)
Fang Li, Frederike Jörg, Xinyu Li & Talitha Feenstra. (2022) A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process. PharmacoEconomics 40:11, pages 1015-1032.
Crossref
Crossref
Roger S. McIntyre, Allan H. Young & Peter M. Haddad. (2018) Rethinking the spectrum of mood disorders: implications for diagnosis and management – Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September 2017, Paris, France. Therapeutic Advances in Psychopharmacology 8:1_suppl, pages 1-16.
Crossref
Crossref
Eduard Vieta & José Manuel Montes. (2017) A Review of Asenapine in the Treatment of Bipolar Disorder. Clinical Drug Investigation 38:2, pages 87-99.
Crossref
Crossref
Ifigeneia Mavranezouli & Joran Lokkerbol. (2016) A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder. PharmacoEconomics 35:3, pages 271-296.
Crossref
Crossref
Sergio De Filippis, Ilaria Cuomo, Georgios D. Kotzalidis, Daniela Pucci, Pietro Zingaretti, Raffaella Porrari, Camilla Fini, Paola Motta, Matteo Caloro & Paolo Girardi. (2016) Does the efficacy of asenapine in bipolar disorder increase in the presence of comorbidity with a substance use disorder? A naturalistic study. Therapeutic Advances in Psychopharmacology 7:2, pages 67-77.
Crossref
Crossref
Ather Muneer. (2017) Mixed States in Bipolar Disorder: Etiology, Pathogenesis and Treatment. Chonnam Medical Journal 53:1, pages 1.
Crossref
Crossref
Ana Flávia Barros da Silva Lima, Luciane Cruz, Mírian Cohen, Jacques José Zimmermann & Sandro René Pinto de Sousa Miguel. 2017. Mental Health Economics. Mental Health Economics
299
311
.
Donatella Marazziti, Federico Mucci, Stefano Baroni & Armando Piccinni. (2016) Asenapine augmentation in bipolar disorders: a case series. Clinical Case Reports 4:5, pages 499-504.
Crossref
Crossref
Erin Grinshteyn & Jeanne Wendel. 2016. Quality Improvement in Behavioral Health. Quality Improvement in Behavioral Health
9
32
.
I. Grande, D. Hidalgo-Mazzei, E. Nieto, M. Mur, C. Sàez, I. Forcada & E. Vieta. (2020) Asenapine prescribing patterns in the treatment of manic in- and outpatients: Results from the MANACOR study. European Psychiatry 30:4, pages 528-534.
Crossref
Crossref
Chiara Caresano, Guido Di Sciascio, Andrea Fagiolini, Giuseppe Maina, Giulio Perugi, Claudio Ripellino & Claudio Vampini. (2014) Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context. Advances in Therapy 31:8, pages 873-890.
Crossref
Crossref